MedBud has been incorporated as a non-profit organisation, with Dr. Tahzid Ahsan (Specialist Psychiatrist) joining as medical director Announcement on X/Twitter

Back to Lumir® or All Oil Concentrates

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This product was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Dosing Look-Up Table (Estimated)

0.01/g0/mg THC5/mg CBD
0.05/g0/mg THC25/mg CBD
0.1/g0/mg THC50/mg CBD
0.15/g0/mg THC75/mg CBD
0.2/g0/mg THC100/mg CBD
0.25/g0/mg THC125/mg CBD
0.3/g0/mg THC150/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
Australia Lumir®
Designation
T0:C50
Chemotype
Type III: High CBD
Carrier Oil
Medium-Chain Triglycerides
THC Potential Range (±10%)
<1/mg
CBD Potential Range (±10%)
45-55/mg
Cultivated or Packaged in
Flag of Australia Australia
Imported by
United Kingdom CanMart
Imported as
Schedule II: Finished Product

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Discontinued

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

Product DescriptionPatient Reviews

Australia About Cannim Australia Pty Ltd

Lumir® Logo

We are a leading global cannabis company providing GACP and GMP certified medical solutions to deliver better physical and mental health outcomes for patients around the world.

Pioneering better health outcomes for those in need by harnessing the power of therapeutic cannabis.

Based in Sydney, Australia, Cannim was established in 2017 to bring the benefits of medicinal cannabis to the world.

Back in 2017, Cannabis was still stigmatised and cultivation considered an art form. Built on the 3 core pillars of Safety, Science, and Scale, Cannim established an organisation that could show people that Cannabis was a real medicine, consistently develop it to pharmaceutical standards, and establish networks to reach a wide audience of needy people.

Just 4 years later, Cannim cultivates in Jamaica and Australia, and established a network of EU GMP manufacturers as well as formed alliances in education and healthcare, offering products & services to bring relief in many forms to people across the world.

This industry is nascent and this is only the beginning of the journey to establish Cannabis as a reputable medicine around the world. Cannim continues to create scale in its operations, giving us the ability to meet the needs of the ever-growing body of medicinal cannabis users. Cannim is pioneering the development of the category, creating new ways of administration for patients, leading research and education into the effects of cannabis on a variety of conditions, pioneering its usefulness for others, and ensuring those in need get what they need when they need it at a price that's fair.

cannim.com

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)